Literature DB >> 23843664

Nonparametric inference for assessing treatment efficacy in randomized clinical trials with a time-to-event outcome and all-or-none compliance.

Robert M Elashoff1, Gang Li, Ying Zhou.   

Abstract

To evaluate the biological efficacy of a treatment in a randomized clinical trial, one needs to compare patients in the treatment arm who actually received treatment with the subgroup of patients in the control arm who would have received treatment had they been randomized into the treatment arm. In practice, subgroup membership in the control arm is usually unobservable. This paper develops a nonparametric inference procedure to compare subgroup probabilities with right-censored time-to-event data and unobservable subgroup membership in the control arm. We also present a procedure to estimate the onset and duration of treatment effect. The performance of our method is evaluated by simulation. An illustration is given using a randomized clinical trial for melanoma.

Entities:  

Keywords:  Biological efficacy; Censoring; Counting process; Martingale; Noncompliance; Survival probability

Year:  2012        PMID: 23843664      PMCID: PMC3635705          DOI: 10.1093/biomet/ass004

Source DB:  PubMed          Journal:  Biometrika        ISSN: 0006-3444            Impact factor:   2.445


  11 in total

Review 1.  What is meant by intention to treat analysis? Survey of published randomised controlled trials.

Authors:  S Hollis; F Campbell
Journal:  BMJ       Date:  1999-09-11

2.  Estimating efficacy in clinical trials with clustered binary responses.

Authors:  Jeffrey M Albert
Journal:  Stat Med       Date:  2002-03-15       Impact factor: 2.373

3.  A causal proportional hazards estimator for the effect of treatment actually received in a randomized trial with all-or-nothing compliance.

Authors:  T Loeys; E Goetghebeur
Journal:  Biometrics       Date:  2003-03       Impact factor: 2.571

4.  Causal proportional hazards models and time-constant exposure in randomized clinical trials.

Authors:  T Loeys; E Goetghebeur; A Vandebosch
Journal:  Lifetime Data Anal       Date:  2005-12       Impact factor: 1.588

5.  Adjusting for non-compliance and contamination in randomized clinical trials.

Authors:  J Cuzick; R Edwards; N Segnan
Journal:  Stat Med       Date:  1997-05-15       Impact factor: 2.373

6.  Randomized consent designs for clinical trials: an update.

Authors:  M Zelen
Journal:  Stat Med       Date:  1990-06       Impact factor: 2.373

7.  On estimating efficacy from clinical trials.

Authors:  A Sommer; S L Zeger
Journal:  Stat Med       Date:  1991-01       Impact factor: 2.373

8.  Sentinel-node biopsy or nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

9.  Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study.

Authors:  M Margaret Kemeny; Sudeshna Adak; Bruce Gray; John S Macdonald; Thomas Smith; Stuart Lipsitz; Elin R Sigurdson; Peter J O'Dwyer; Al B Benson
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

10.  A new design for randomized clinical trials.

Authors:  M Zelen
Journal:  N Engl J Med       Date:  1979-05-31       Impact factor: 91.245

View more
  3 in total

1.  Weighted estimators of the complier average causal effect on restricted mean survival time with observed instrument-outcome confounders.

Authors:  Sai H Dharmarajan; Yun Li; Douglas Lehmann; Douglas E Schaubel
Journal:  Biom J       Date:  2020-12-21       Impact factor: 2.207

2.  Latent subgroup analysis of a randomized clinical trial through a semiparametric accelerated failure time mixture model.

Authors:  L Altstein; G Li
Journal:  Biometrics       Date:  2013-02-05       Impact factor: 2.571

3.  A semiparametric linear transformation model to estimate causal effects for survival data.

Authors:  Huazhen Lin; Yi Li; Liang Jiang; Gang Li
Journal:  Can J Stat       Date:  2013-11-14       Impact factor: 0.875

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.